Shares of Oncolytics Biotech (ONCY) rallied 18.2% on Friday after the company announced that it is seeking an accelerated pathway for the approval of its lead developmental candidate, pelareorep, for the metastatic breast cancer (mBC) indication. The stock is also gaining today. Pelareorep follows a unique mechanism of action, different from currently available therapeutics for this indication. It selectively targets cancer cells, triggering a cascade of inflammatory responses (which include PDL1 upregulati ...

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registrationenabling studies SAN DIEGO and CALGARY, AB, Oct. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a corporate update to pr ...

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorepbased therapy in advanced or metastatic breast cancer Over half of BRACELET-1 patients in the pelareorep + chemotherapy ...

SAN DIEGO and CALGARY, AB, Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference, which is taking place September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. Chief Medical Officer Tom Heineman, M.D., Ph.D., will participate in a fire ...

SAN DIEGO and CALGARY, AB, Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat at Canaccord Genuity's 44th Annual Growth Conference, which is taking place August 13-15, 2024 at the InterContinental Boston Hotel in Boston, MA. Additional details on the fireside chat can be found below. Date: Tuesday, August ...

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and six months ended June 30, 2024 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | | | June 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2024 | | 2023 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 24,850 | $ | 34,912 | | Other rec ...

Core Insights - Oncolytics Biotech Inc. is advancing its immunotherapeutic agent, pelareorep, towards registration-enabling studies for breast and pancreatic cancers, with positive feedback from the FDA regarding the study design for HR+/HER2- metastatic breast cancer [1][2][3] - The company has initiated the GOBLET study for pancreatic cancer, evaluating pelareorep in combination with modified FOLFIRINOX, supported by a $5 million grant from the Pancreatic Cancer Action Network (PanCAN) [1][4] - Oncolytics has a cash position of $24.9 million, providing a runway through key milestones into 2025 [1][7] Regulatory and Clinical Developments - The FDA has supported the use of progression-free survival as the primary endpoint and overall survival as a secondary endpoint for the pelareorep study in HR+/HER2- metastatic breast cancer [3] - The GOBLET study's fifth cohort will assess pelareorep combined with mFOLFIRINOX, with or without atezolizumab, in newly diagnosed pancreatic ductal adenocarcinoma patients [4][5] - A collaboration with the Global Coalition for Adaptive Research (GCAR) is underway to evaluate pelareorep in first-line metastatic pancreatic cancer, which has received Fast Track Designation from the FDA [5][6] Financial Performance - For Q2 2024, Oncolytics reported a net loss of $7.3 million, slightly improved from a net loss of $7.4 million in Q2 2023, with a basic and diluted loss per share of $0.10 [7][11] - Research and development expenses increased to $4.6 million in Q2 2024 from $3.7 million in Q2 2023, primarily due to higher clinical trial costs [7][11] - The company’s total assets as of June 30, 2024, were $32.1 million, down from $38.8 million at the end of 2023 [10] Upcoming Milestones - Overall survival results from the BRACELET-1 trial in HR+/HER2- metastatic breast cancer are expected in the second half of 2024 [9] - Finalization of the master protocol for the adaptive registration-enabling trial for pelareorep in first-line pancreatic cancer is anticipated in H2 2024 [9] - An update on the safety run-in for the GOBLET mFOLFIRINOX cohort is expected in H1 2025 [9]

SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the second quarter 2024. A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking h ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. The article continued: According to the World Health Organization, the global cancer burden is growing amidst a mounting need for services. As well, an alarming trend is emerging, where cancer cases in younger people are rising sharply. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that the Company received productive feedback from its T ...

Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 SAN DIEGO and CALGARY, AB, June 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the in ...